drugset
drugset / Trial / NCT07576010

Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

NCT07576010 ↗

Phase 1 Active not recruiting 30 enrolled Daihong Liu
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.

Timeline

Start
2025-01-17
Primary completion
2027-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylprednisolone Other / unclassified 0.5 mg/kg —
Subject Ruxolitinib Small molecule — —

Indications

acute graft versus host disease